2023-08-29 09:05:33 ET
More on TScan Therapeutics
- TScan Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- TScan gains as FDA clears studies for T cell therapy candidate
- TScan Therapeutics stock slides on pricing $140M securities offering
- TScan jumps 102% after deal with Amgen for Crohn’s disease
- TScan stock rises ~15% on FDA nod to start trials of cancer drugs
- Seeking Alpha’s Quant Rating on TScan Therapeutics
- Earnings data for TScan Therapeutics
For further details see:
TScan Therapeutics gets FDA's IND clearance for its fourth T cell therapy targeting solid tumors